Multiple sclerosis (MS) is associated with a variety of symptoms and functional deficits that result in a range of progressive impairments and handicap. Symptoms that contribute to loss of independence and restrictions in social activities lead to continuing decline in quality of life.
Our aim is to give an updated overview on the management… read more »
Background:
A higher incidence of certain autoimmune disorders has been reported in Down’s syndrome (DS) but only 1 case of DS associated with multiple sclerosis (MS) has been published to date.
Methods:
We performed a calculation based on population and prevalence
NEW YORK, Sept 26 (Reuters) – Biogen Idec Inc. and Elan Corp. on Monday said they have submitted new safety data to U.S. regulators on their drug Tysabri, in hopes of getting the withdrawn multiple sclerosis treatment back on the market.
The companies, which withdrew the injectable medicine in February, said they have asked the U.S. Food and Drug Administration to review the… read more »
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
BACKGROUND…
A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.
Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favoured ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012)… read more »
September 21, 2005
Yes, I am raising my recommendation for vitamin D from 400 IU to 1,000 IU per day. That may sound like quite a leap, but evidence has been accumulating to suggest that the 400 IU now recommended for adults isn’t enough for optimum health. We need vitamin d to facilitate calcium absorption and to promote bone mineralization as well as for protection
HOUSTON (Reuters) –
The discovery could one day lead to the prevention, and possibly to the treatment, of autoimmune diseases such as Type 1
OBJECTIVE: To assess the prevalence of multiple sclerosis (MS), calculated as point prevalence on 31 December 1997, in the province of Genoa, North-western Italy.
